The global Cardiogenic Shock Treatment Market is expected to garner a market value of US$ 0.9 Billion in 2023 and is expected to accumulate a market value of US$ 1.77 Billion by registering a CAGR of 7% in the forecast period 2023 to 2033. The market for Cardiogenic Shock Treatment registered a CAGR of 3.5% in the historical period 2018 to 2022.
The Cardiogenic Shock Treatment market is a segment of the healthcare industry that deals with the effective management of the condition. The global cardiogenic shock treatment market is expected to grow at a significant rate in the coming years, driven by a growing incidence of heart disease and an aging population. The market offers a range of products and services for its effective management and treatments including medications which help to increase blood pressure and improve blood flow, inotropes which improve the heart's ability to contract and pump blood, medical devices to support the heart and improve blood flow and so on.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 0.9 Billion |
| Anticipated Forecast Value (2033) | US$ 1.77 Billion |
| Projected Growth Rate (2023 to 2033) | 7% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider, Future Market Insights- the market for Cardiogenic Shock Treatment reflected a value of 3.5% during the historical period, 2018 to 2022. Factors driving market growth include the increasing adoption of mechanical support devices such as Impella and ECMO, which provide circulatory support and improve blood flow in patients with cardiogenic shock. In addition, the development of new treatment options and technologies, such as stem cell therapy and gene therapy, may also contribute to market growth.
The primary goal of cardiogenic shock treatment is to restore blood flow to the body's vital organs, such as the brain, kidneys, and lungs. Treatment may involve a combination of medications and medical devices, depending on the underlying cause of the condition. Looking ahead to the period from 2023 to 2033, the Cardiogenic Shock Treatment market is expected to continue to grow in the coming years, driven by a combination of demographic, technological, and economic factors. Cardiogenic Shock is expected to remain a major health concern globally, which will drive demand for Cardiogenic Shock Treatment. In recent years, several new Cardiogenic Shock vaccine options have emerged for Cardiogenic Shock, pushing the market for Cardiogenic Shock Treatment is expected to register a CAGR of 7% in the forecast period 2023 to 2033.
Increasing incidence of heart disease to push the market growth
The increasing incidence of heart disease is a major factor driving the growth of the cardiogenic shock treatment market. Heart disease is a leading cause of death globally and is caused by a range of factors, including unhealthy lifestyle choices, genetic predisposition, and underlying medical conditions such as hypertension and diabetes.
Cardiogenic shock is a severe complication of heart disease and is most commonly caused by a heart attack. As the incidence of heart disease continues to rise, so does the incidence of cardiogenic shock. According to the American Heart Association, approximately 805,000 Americans have a heart attack each year, and around 7-8% of these patients go on to develop cardiogenic shock.
In addition to heart attacks, other cardiovascular conditions such as heart failure, arrhythmias, and valve disorders can also lead to cardiogenic shock. As the population ages and the prevalence of these conditions increases, so does the incidence of cardiogenic shock.
The increasing incidence of heart disease has led to a growing demand for effective treatments for cardiogenic shock, which has contributed to the growth of the cardiogenic shock treatment market. Advancements in mechanical support devices, such as Impella and ECMO, have significantly improved the prognosis for patients with cardiogenic shock, and the development of new treatment options such as stem cell therapy and gene therapy may also contribute to market growth in the future.
Overall, the increasing incidence of heart disease is a key driver of the growth of the cardiogenic shock treatment market, and is expected to continue to fuel demand for effective treatment options in the coming years.
Principal Consultant
Expensive Cost of Treatment to restrict Market Growth
The cost of treatment for cardiogenic shock can be significant, particularly for mechanical support devices such as Impella and ECMO. This can limit access to these treatments for some patients and may also impact market growth. Additionally, the development and approval of new treatments for cardiogenic shock can be a lengthy and costly process, which can limit the availability of new treatment options and contribute to market stagnation.
Increasing Prevalence of Cardiovascular Diseases Shaping Landscape for Cardiogenic Shock Treatment in South & East Asia
The cardiogenic shock treatment market in South and East Asia is growing, driven by several factors including the increasing prevalence of cardiovascular diseases, a growing aging population, and improving healthcare infrastructure in the region.
In countries such as India, China, and Japan, the incidence of cardiovascular diseases is increasing due to changing lifestyles, unhealthy diets, and high levels of pollution. As a result, the number of patients with cardiogenic shock is also increasing, leading to a growing demand for effective treatment options.
In addition to the increasing prevalence of cardiovascular diseases, the aging population in the region is also contributing to market growth. As the population ages, the risk of developing cardiovascular diseases and other chronic conditions increases, leading to a greater demand for healthcare services, including cardiogenic shock treatment.
Furthermore, the healthcare infrastructure in many countries in South and East Asia is improving, with increasing investment in medical facilities and equipment, as well as greater access to advanced medical treatments. This is leading to a growing number of hospitals and medical centers offering cardiogenic shock treatment options, which is helping to expand the market.
Increasing Focus on Technological advancements Shaping Landscape for Cardiogenic Shock Treatment in North America
North America is anticipated to acquire a market share of about 40% in the forecast period. North America has one of the highest incidence rates of cardiovascular disease in the world, with heart attacks being a leading cause of death in the region. This high incidence of cardiovascular disease has led to a growing demand for effective treatment options for cardiogenic shock.
Furthermore, mechanical support devices such as Impella and ECMO have become increasingly common in the treatment of cardiogenic shock, and North America has been at the forefront of the development and use of these devices. These devices have significantly improved the prognosis for patients with cardiogenic shock and are driving market growth.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Hospitals segment to hold a significant share and push market growth
Hospitals are the primary care providers for patients with cardiogenic shock, and they are equipped with the necessary medical equipment and trained personnel to provide critical care and interventions for these patients. In addition, many hospitals have specialized cardiac care units or departments that focus specifically on the treatment of cardiovascular diseases, including cardiogenic shock.
Furthermore, hospitals are also the primary site for medical device implantation procedures such as Impella, ECMO, and IABPs. These devices require specialized training and expertise to implant and manage, and hospitals are well-equipped to provide these services.
While cardiac centers and ambulatory surgical centers also play an important role in the treatment of cardiogenic shock, they are typically more specialized and may not provide the same level of critical care as hospitals. As a result, hospitals are likely to account for a significant share of the cardiogenic shock treatment market in the coming years.
Treatment using devices to take the lead and drive market growth
Medical devices such as Impella, ECMO, and intra-aortic balloon pumps (IABPs) are increasingly being used in the treatment of cardiogenic shock. These devices provide mechanical support to the heart and help to restore blood flow and oxygen to the body's organs. They have been shown to significantly improve survival rates and outcomes for patients with cardiogenic shock.
In addition to these devices, there are also several other medical devices and technologies that are being developed and tested for the treatment of cardiogenic shock, including extracorporeal carbon dioxide removal (ECCO2R) devices, micro axial flow pumps, and novel ventricular assist devices (VADs). These devices have the potential to further improve outcomes for patients with cardiogenic shock and are expected to drive growth in the medical devices segment of the market.
While medications and surgery are also important treatment options for cardiogenic shock, they are typically used in conjunction with medical devices rather than as standalone treatments. As a result, the medical devices segment is likely to account for a significant share of the cardiogenic shock treatment market in the coming years.
Key players in the market include companies such as Getinge AB, Par Pharmaceutical, Abbott, Viatris Inc., F. Hoffman-La Roche Ltd, Bayer AG, Terumo Corporation, Medtronic, AbioMed, Astrazeneca along with healthcare providers and technology companies among other global players.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 0.9 Billion |
| Market Value in 2033 | US$ 1.77 Billion |
| Growth Rate | CAGR of 7% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled | Getinge AB, Par Pharmaceutical, Abbott, Viatris Inc., F. Hoffman-La Roche Ltd, Bayer AG, Terumo Corporation, Medtronic, AbioMed, Astrazeneca |
| Customization | Available Upon Request |
The market is valued at US$ 0.9 billion in 2023.
Getinge AB, Par Pharmaceutical, and Abbott are the key market players.
The market is forecast to register a CAGR of 7% through 2033.
The market is expected to reach US$ 1.77 billion by 2033.
The market registered a CAGR of 3.5% From 2018 to 2022.
1. Executive Summary | Cardiogenic Shock Treatment Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2022 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2022 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2022 to 2033, By Treatment Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Treatment Type, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment Type, 2022 to 2033 5.3.1. In-Vitro Test Kits 5.3.2. Drugs 5.3.3. Devices 5.4. Y-o-Y Growth Trend Analysis By Treatment Type, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Treatment Type, 2022 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2022 to 2033, By End-User 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By End-User, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End-User, 2022 to 2033 6.3.1. Cardiac Catheterization Labs 6.3.2. Hospitals 6.3.3. Ambulatory Surgical Centres 6.4. Y-o-Y Growth Trend Analysis By End-User, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By End-User, 2022 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2022 to 2033, By Region 7.1. Introduction 7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2022 to 2033 7.3.1. North America 7.3.2. Latin America 7.3.3. Europe 7.3.4. South Asia 7.3.5. East Asia 7.3.6. Oceania 7.3.7. MEA 7.4. Market Attractiveness Analysis By Region 8. North America Market Analysis 2018 to 2022 and Forecast 2022 to 2033, By Country 8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2033 8.2.1. By Country 8.2.1.1. U.S. 8.2.1.2. Canada 8.2.2. By Treatment Type 8.2.3. By End-User 8.3. Market Attractiveness Analysis 8.3.1. By Country 8.3.2. By Treatment Type 8.3.3. By End-User 8.4. Key Takeaways 9. Latin America Market Analysis 2018 to 2022 and Forecast 2022 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2033 9.2.1. By Country 9.2.1.1. Brazil 9.2.1.2. Mexico 9.2.1.3. Rest of Latin America 9.2.2. By Treatment Type 9.2.3. By End-User 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Treatment Type 9.3.3. By End-User 9.4. Key Takeaways 10. Europe Market Analysis 2018 to 2022 and Forecast 2022 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2033 10.2.1. By Country 10.2.1.1. Germany 10.2.1.2. U.K. 10.2.1.3. France 10.2.1.4. Spain 10.2.1.5. Italy 10.2.1.6. Rest of Europe 10.2.2. By Treatment Type 10.2.3. By End-User 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Treatment Type 10.3.3. By End-User 10.4. Key Takeaways 11. South Asia Market Analysis 2018 to 2022 and Forecast 2022 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2033 11.2.1. By Country 11.2.1.1. India 11.2.1.2. Malaysia 11.2.1.3. Singapore 11.2.1.4. Thailand 11.2.1.5. Rest of South Asia 11.2.2. By Treatment Type 11.2.3. By End-User 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Treatment Type 11.3.3. By End-User 11.4. Key Takeaways 12. East Asia Market Analysis 2018 to 2022 and Forecast 2022 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2033 12.2.1. By Country 12.2.1.1. China 12.2.1.2. Japan 12.2.1.3. South Korea 12.2.2. By Treatment Type 12.2.3. By End-User 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Treatment Type 12.3.3. By End-User 12.4. Key Takeaways 13. Oceania Market Analysis 2018 to 2022 and Forecast 2022 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2033 13.2.1. By Country 13.2.1.1. Australia 13.2.1.2. New Zealand 13.2.2. By Treatment Type 13.2.3. By End-User 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Treatment Type 13.3.3. By End-User 13.4. Key Takeaways 14. MEA Market Analysis 2018 to 2022 and Forecast 2022 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2033 14.2.1. By Country 14.2.1.1. GCC Countries 14.2.1.2. South Africa 14.2.1.3. Israel 14.2.1.4. Rest of MEA 14.2.2. By Treatment Type 14.2.3. By End-User 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Treatment Type 14.3.3. By End-User 14.4. Key Takeaways 15. Key Countries Market Analysis 15.1. USA 15.1.1. Pricing Analysis 15.1.2. Market Share Analysis, 2022 15.1.2.1. By Treatment Type 15.1.2.2. By End-User 15.2. Canada 15.2.1. Pricing Analysis 15.2.2. Market Share Analysis, 2022 15.2.2.1. By Treatment Type 15.2.2.2. By End-User 15.3. Brazil 15.3.1. Pricing Analysis 15.3.2. Market Share Analysis, 2022 15.3.2.1. By Treatment Type 15.3.2.2. By End-User 15.4. Mexico 15.4.1. Pricing Analysis 15.4.2. Market Share Analysis, 2022 15.4.2.1. By Treatment Type 15.4.2.2. By End-User 15.5. Germany 15.5.1. Pricing Analysis 15.5.2. Market Share Analysis, 2022 15.5.2.1. By Treatment Type 15.5.2.2. By End-User 15.6. United Kingdom 15.6.1. Pricing Analysis 15.6.2. Market Share Analysis, 2022 15.6.2.1. By Treatment Type 15.6.2.2. By End-User 15.7. France 15.7.1. Pricing Analysis 15.7.2. Market Share Analysis, 2022 15.7.2.1. By Treatment Type 15.7.2.2. By End-User 15.8. Spain 15.8.1. Pricing Analysis 15.8.2. Market Share Analysis, 2022 15.8.2.1. By Treatment Type 15.8.2.2. By End-User 15.9. Italy 15.9.1. Pricing Analysis 15.9.2. Market Share Analysis, 2022 15.9.2.1. By Treatment Type 15.9.2.2. By End-User 15.10. India 15.10.1. Pricing Analysis 15.10.2. Market Share Analysis, 2022 15.10.2.1. By Treatment Type 15.10.2.2. By End-User 15.11. Malaysia 15.11.1. Pricing Analysis 15.11.2. Market Share Analysis, 2022 15.11.2.1. By Treatment Type 15.11.2.2. By End-User 15.12. Singapore 15.12.1. Pricing Analysis 15.12.2. Market Share Analysis, 2022 15.12.2.1. By Treatment Type 15.12.2.2. By End-User 15.13. Thailand 15.13.1. Pricing Analysis 15.13.2. Market Share Analysis, 2022 15.13.2.1. By Treatment Type 15.13.2.2. By End-User 15.14. China 15.14.1. Pricing Analysis 15.14.2. Market Share Analysis, 2022 15.14.2.1. By Treatment Type 15.14.2.2. By End-User 15.15. Japan 15.15.1. Pricing Analysis 15.15.2. Market Share Analysis, 2022 15.15.2.1. By Treatment Type 15.15.2.2. By End-User 15.16. South Korea 15.16.1. Pricing Analysis 15.16.2. Market Share Analysis, 2022 15.16.2.1. By Treatment Type 15.16.2.2. By End-User 15.17. Australia 15.17.1. Pricing Analysis 15.17.2. Market Share Analysis, 2022 15.17.2.1. By Treatment Type 15.17.2.2. By End-User 15.18. New Zealand 15.18.1. Pricing Analysis 15.18.2. Market Share Analysis, 2022 15.18.2.1. By Treatment Type 15.18.2.2. By End-User 15.19. GCC Countries 15.19.1. Pricing Analysis 15.19.2. Market Share Analysis, 2022 15.19.2.1. By Treatment Type 15.19.2.2. By End-User 15.20. South Africa 15.20.1. Pricing Analysis 15.20.2. Market Share Analysis, 2022 15.20.2.1. By Treatment Type 15.20.2.2. By End-User 15.21. Israel 15.21.1. Pricing Analysis 15.21.2. Market Share Analysis, 2022 15.21.2.1. By Treatment Type 15.21.2.2. By End-User 16. Market Structure Analysis 16.1. Competition Dashboard 16.2. Competition Benchmarking 16.3. Market Share Analysis of Top Players 16.3.1. By Regional 16.3.2. By Treatment Type 16.3.3. By End-User 17. Competition Analysis 17.1. Competition Deep Dive 17.1.1. Getinge AB 17.1.1.1. Overview 17.1.1.2. Product Portfolio 17.1.1.3. Profitability by Market Segments 17.1.1.4. Sales Footprint 17.1.1.5. Strategy Overview 17.1.1.5.1. Marketing Strategy 17.1.2. Par Pharmaceutical 17.1.2.1. Overview 17.1.2.2. Product Portfolio 17.1.2.3. Profitability by Market Segments 17.1.2.4. Sales Footprint 17.1.2.5. Strategy Overview 17.1.2.5.1. Marketing Strategy 17.1.3. Abbott 17.1.3.1. Overview 17.1.3.2. Product Portfolio 17.1.3.3. Profitability by Market Segments 17.1.3.4. Sales Footprint 17.1.3.5. Strategy Overview 17.1.3.5.1. Marketing Strategy 17.1.4. Viatris Inc. 17.1.4.1. Overview 17.1.4.2. Product Portfolio 17.1.4.3. Profitability by Market Segments 17.1.4.4. Sales Footprint 17.1.4.5. Strategy Overview 17.1.4.5.1. Marketing Strategy 17.1.5. F. Hoffman-La Roche Ltd 17.1.5.1. Overview 17.1.5.2. Product Portfolio 17.1.5.3. Profitability by Market Segments 17.1.5.4. Sales Footprint 17.1.5.5. Strategy Overview 17.1.5.5.1. Marketing Strategy 17.1.6. Bayer AG 17.1.6.1. Overview 17.1.6.2. Product Portfolio 17.1.6.3. Profitability by Market Segments 17.1.6.4. Sales Footprint 17.1.6.5. Strategy Overview 17.1.6.5.1. Marketing Strategy 17.1.7. Terumo Corporation 17.1.7.1. Overview 17.1.7.2. Product Portfolio 17.1.7.3. Profitability by Market Segments 17.1.7.4. Sales Footprint 17.1.7.5. Strategy Overview 17.1.7.5.1. Marketing Strategy 17.1.8. Medtronic 17.1.8.1. Overview 17.1.8.2. Product Portfolio 17.1.8.3. Profitability by Market Segments 17.1.8.4. Sales Footprint 17.1.8.5. Strategy Overview 17.1.8.5.1. Marketing Strategy 17.1.9. AbioMed 17.1.9.1. Overview 17.1.9.2. Product Portfolio 17.1.9.3. Profitability by Market Segments 17.1.9.4. Sales Footprint 17.1.9.5. Strategy Overview 17.1.9.5.1. Marketing Strategy 17.1.10. Astrazeneca 17.1.10.1. Overview 17.1.10.2. Product Portfolio 17.1.10.3. Profitability by Market Segments 17.1.10.4. Sales Footprint 17.1.10.5. Strategy Overview 17.1.10.5.1. Marketing Strategy 18. Assumptions & Acronyms Used 19. Research Methodology
Explore Healthcare Insights
View Reports
Cardiogenic Shock Treatment Market
